Flow Cytometry Analysis of the Reactive Oxygen Species in Immature Granulocytes in Septic Patient
NCT ID: NCT03846596
Last Updated: 2020-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
34 participants
OBSERVATIONAL
2019-03-26
2020-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Interest of Leucocyte Immunophenotyping During the Acute Phase of Sepsis
NCT01995448
Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
NCT05110937
Innate Lymphoid Cells in Septic Shock
NCT03297203
Role of Inflammatory Markers in Sepsis
NCT06111963
Can Measurement of Neutrophil-derived ROS Production be a Novel Biomarker of Sepsis?
NCT05968287
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Evaluated
An additional blood tube will be taken from patients hospitalized in intensive care or emergency department for acute sepsis
Additional blood tube
Additional blood tube during care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Additional blood tube
Additional blood tube during care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Active cancer
* HIV
* Hematological or inflammatory diseases
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Limoges
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas DAIX, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Limoges
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Limoges university Hospital
Limoges, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
87RI18-0031 (SEPSIROS)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.